Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05225298 · ClinicalTrials.gov registry record · NA
SARS-COV-2 Screening in Dialysis Facilities
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 2,389
- Enrollment target
NCT05225298: Completed NA study, sponsored by Stanford University.
NCT05225298 is a NA study that has completed, run by Stanford University. The registered enrollment target is 2,389 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05225298, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,389 participants
- Enrollment target
Study Summary
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Interventions
- BEHAVIORAL Offering SARS-CoV-2 test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,389 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2023-10-01 |
| Phase | NA |
What the finished NCT05225298 record still lists
NCT05225298 is an interventional study that assigns participants to a tested intervention. Its 2,389 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 1 intervention - of which Offering SARS-CoV-2 test is the first listed.
NCT05225298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05225298 about?
NCT05225298 is a clinical study titled "SARS-COV-2 Screening in Dialysis Facilities". Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and ...
What is the current status of trial NCT05225298?
This trial is currently completed. It is a NA study. The enrollment target is 2,389 participants. The study started on 2023-02-06. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT05225298?
The interventions under investigation include: Offering SARS-CoV-2 test (BEHAVIORAL).
Who is sponsoring clinical trial NCT05225298?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05225298's enrollment target sits among peer trials
2,389 46th of 2000 higher than 1,955 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI